Research Topic · Peer-Reviewed

Hematological Malignancies

Hematological malignancies are cancers that originate in the blood, bone marrow, and lymphatic system. They are conventionally grouped into three broad families: the leukemias, the lymphomas comprising both Hodgkin and non-Hodgkin types, and the plasma-cell disorders such as myeloma and related entities including Wa…

Curated from this journal's research 📚 12 peer-reviewed articles cited Cited 40× across the literature 🔖 ISSN 2372-6601

Overview

Hematological malignancies are cancers that originate in the blood, bone marrow, and lymphatic system. They are conventionally grouped into three broad families: the leukemias, the lymphomas comprising both Hodgkin and non-Hodgkin types, and the plasma-cell disorders such as myeloma and related entities including Waldenstrom's macroglobulinemia. Classification rests on the cell lineage of origin, principally the distinction between myeloid and lymphoid derivation, and on the maturation stage at which malignant transformation occurs. That transformation, termed leukemogenesis or lymphomagenesis, results from acquired genetic and molecular lesions that subvert the normal control of proliferation, differentiation, and survival in hematopoietic and lymphoid cells. Because the malignant clone competes with and displaces normal marrow elements, these diseases characteristically disrupt healthy hematopoiesis and impair immune function, producing cytopenias and susceptibility to infection. Aggressive disease may also perturb hemostasis, as reflected in alterations of von Willebrand factor and ADAMTS13. Laboratory parameters, including markers such as lactate dehydrogenase, aid in assessing tumor burden and prognosis. Management spans cytotoxic chemotherapy, increasingly precise targeted and molecular therapies directed at specific lesions, and hematopoietic stem-cell transplantation, the success of which depends on effective mobilization and collection of stem cells. Experimental approaches, including cholesterol-conjugated small interfering RNA for gene silencing in hematopoietic and lymphoid cells, continue to expand the therapeutic landscape.

Research published in this journal

12 peer-reviewed articles, ranked by relevance. Each links to its DOI.

How this research is being cited

The 12 articles above have been cited 40 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Nov 2026.

A sample of recent works citing this journal's research on Hematological Malignancies, linking to each citing work.

Editorial oversight

Curated from peer-reviewed research published in Journal of Hematology and Oncology Research (ISSN 2372-6601).

Journal editorial board
Krzysztof Roszkowski · Poland Agnieszka Żyromska · Poland Almuradova Dilbar Muradovna · Uzbekistan

This page summarises published research for orientation; it is not medical or professional advice.